# Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

> **NCT03578640** · PHASE3 · COMPLETED · sponsor: **King Fahad Medical City** · enrollment: 30 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Elbasvir, Grazoprevir 50-100Mg Oral Tablet

## Key facts

- **NCT ID:** NCT03578640
- **Lead sponsor:** King Fahad Medical City
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03578640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03578640, "Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03578640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*